RecruitingNot ApplicableNCT05309850
Primary Prevention With the Lifestyle Tool
Primary Disease Prevention With the Lifestyle Tool
Sponsor
Region Skane
Enrollment
90,000 participants
Start Date
Apr 5, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
In this study participants will be randomized to use a digital lifestyle tool over three years or to a control group without access to the tool. The investigators will prospectively via clinical registries follow the incidence and development of type 2 diabetes and cardiovascular disease in those using the tool regularly and those in the control group.
Eligibility
Min Age: 35 Years
Inclusion Criteria2
- informed consent
- Age above 35 years
Exclusion Criteria3
- type 1 diabetes, MODY or secondary diabetes
- conditions or treatments that in the judgement of the Investigator could affect the study evaluation
- connection with the study team, funders, authorities, universities or other public or private bodies in such a way that specific interests in the study outcomes could be suspected.
Interventions
BEHAVIORALLifestyle tool
Regular use of the digital Lifestyle tool
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05309850
Related Trials
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT0729648446 locations
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731153 locations
Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care
NCT071694221 location
Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes
NCT068364791 location
The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases
NCT0690977369 locations